Patent · US Active

Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders

US8222217B2 · kind B2 · utility

1Cited by

7References

28Claims

0Family size

Assignee

Alize Pharma SAS · FR

Inventors

Ezio Ghigo · Torino, IT
Riccarda Granata · Torino, IT
Aart Jan Van Der Lely · Bergschenhoek, NL

Key dates

Filing date	May 30, 2008
Grant date	Jul 17, 2012
Priority date	—
Expiry date	May 30, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An isolated polypeptide comprising any amino acid fragment of unacylated ghrelin or any analog thereof, wherein the polypeptide has an activity selected from the group consisting of a) decreasing blood glucose levels; b) increasing insulin secretion an/or sensitivity; c) binding to insulin-secreting cells; and d) promoting survival of insulin-secreting cells. As well as the use of the polypeptide in the treatment of a disorder associated with impaired glucose metabolism.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.